Belite Study
Phase 1/2, open label, dose-finding followed by a 2-year extension study to evaluate the safety and tolerability of Tinlarebant in adolescent subjects with Stargardt Disease.
Principal Investigator – Dr. Fred Chen
Trial ANZCTR Registry Number: ACTRN12621000549820
For further information contact the Clinical Trials Office on (08) 9381 0750 or email clinicalresearch@lei.org.au
